Cerus (FRA:CU2) YoY EBITDA Growth : 51.43% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Cerus YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cerus's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 51.43%.

Cerus's EBITDA per Share for the three months ended in Mar. 2024 was €-0.03.

Cerus YoY EBITDA Growth Historical Data

The historical data trend for Cerus's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus YoY EBITDA Growth Chart

Cerus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-16.18

34.33

9.85

24.79

25.14

Cerus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															-34.62	-60.61	38.89	113.56	51.43

Cerus YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cerus's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.134	-	-0.179)	/	\| -0.179 \|
=	25.14 %

Cerus's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.034	-	-0.07)	/	\| -0.07 \|
=	51.43 %

Cerus YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cerus's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerus (FRA:CU2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (FRA:CU2) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CERS:USA CU2:Germany

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (FRA:CU2) Headlines

No Headlines